GB201607393D0 - Biomarkers for early diagnosis of ovarian cancer - Google Patents
Biomarkers for early diagnosis of ovarian cancerInfo
- Publication number
- GB201607393D0 GB201607393D0 GBGB1607393.4A GB201607393A GB201607393D0 GB 201607393 D0 GB201607393 D0 GB 201607393D0 GB 201607393 A GB201607393 A GB 201607393A GB 201607393 D0 GB201607393 D0 GB 201607393D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- biomarkers
- ovarian cancer
- early diagnosis
- diagnosis
- early
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1607393.4A GB2549763A (en) | 2016-04-28 | 2016-04-28 | Biomarkers for early diagnosis of ovarian cancer |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1607393.4A GB2549763A (en) | 2016-04-28 | 2016-04-28 | Biomarkers for early diagnosis of ovarian cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
GB201607393D0 true GB201607393D0 (en) | 2016-06-15 |
GB2549763A GB2549763A (en) | 2017-11-01 |
Family
ID=56234031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB1607393.4A Withdrawn GB2549763A (en) | 2016-04-28 | 2016-04-28 | Biomarkers for early diagnosis of ovarian cancer |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2549763A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111735949A (en) * | 2020-07-17 | 2020-10-02 | 北京信诺卫康科技有限公司 | Wnt7a and CA125 combined used as early ovarian cancer biomarker and kit |
CN111735950A (en) * | 2020-07-17 | 2020-10-02 | 北京信诺卫康科技有限公司 | Combination of FGF18 and CA125 as early ovarian cancer biomarker and kit |
CN111912987A (en) * | 2020-08-25 | 2020-11-10 | 北京信诺卫康科技有限公司 | Combination of FGF18 and HE4 as early ovarian cancer biomarker and kit |
CN114015689A (en) * | 2021-10-26 | 2022-02-08 | 江苏大学 | shRNA sequence for specifically inhibiting GOS2 gene expression and application thereof |
CN116716404A (en) * | 2023-06-13 | 2023-09-08 | 中国医学科学院北京协和医院 | Device for distinguishing ovarian clear cell carcinoma from high-grade serous carcinoma based on S100A2 |
CN116790759A (en) * | 2023-08-08 | 2023-09-22 | 潍坊医学院 | Application of PLEC in early diagnosis and treatment of epithelial ovarian cancer |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102368717B1 (en) * | 2018-11-16 | 2022-02-28 | 가톨릭대학교 산학협력단 | Biomarker for predicting development of hereditary ovarian cancer and use thereof |
WO2020101432A1 (en) * | 2018-11-16 | 2020-05-22 | 가톨릭대학교 산학협력단 | Biomarker for predicting onset of hereditary ovarian cancer and use thereof |
CN112951325B (en) * | 2021-02-18 | 2023-04-21 | 北京吉因加医学检验实验室有限公司 | Design method of probe combination for cancer detection and application thereof |
-
2016
- 2016-04-28 GB GB1607393.4A patent/GB2549763A/en not_active Withdrawn
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111735949A (en) * | 2020-07-17 | 2020-10-02 | 北京信诺卫康科技有限公司 | Wnt7a and CA125 combined used as early ovarian cancer biomarker and kit |
CN111735950A (en) * | 2020-07-17 | 2020-10-02 | 北京信诺卫康科技有限公司 | Combination of FGF18 and CA125 as early ovarian cancer biomarker and kit |
CN111735950B (en) * | 2020-07-17 | 2023-07-21 | 北京信诺卫康科技有限公司 | FGF18 and CA125 combined used as early ovarian cancer biomarker and kit |
CN111912987A (en) * | 2020-08-25 | 2020-11-10 | 北京信诺卫康科技有限公司 | Combination of FGF18 and HE4 as early ovarian cancer biomarker and kit |
CN111912987B (en) * | 2020-08-25 | 2023-07-21 | 北京信诺卫康科技有限公司 | FGF18 and HE4 combined used as early ovarian cancer biomarker and kit |
CN114015689A (en) * | 2021-10-26 | 2022-02-08 | 江苏大学 | shRNA sequence for specifically inhibiting GOS2 gene expression and application thereof |
CN116716404A (en) * | 2023-06-13 | 2023-09-08 | 中国医学科学院北京协和医院 | Device for distinguishing ovarian clear cell carcinoma from high-grade serous carcinoma based on S100A2 |
CN116716404B (en) * | 2023-06-13 | 2024-01-30 | 中国医学科学院北京协和医院 | Device for distinguishing ovarian clear cell carcinoma from high-grade serous carcinoma based on S100A2 |
CN116790759A (en) * | 2023-08-08 | 2023-09-22 | 潍坊医学院 | Application of PLEC in early diagnosis and treatment of epithelial ovarian cancer |
CN116790759B (en) * | 2023-08-08 | 2023-12-01 | 潍坊医学院 | Application of PLEC in early diagnosis and treatment of epithelial ovarian cancer |
Also Published As
Publication number | Publication date |
---|---|
GB2549763A (en) | 2017-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB201607393D0 (en) | Biomarkers for early diagnosis of ovarian cancer | |
ZA201701753B (en) | Biomarkers for assessing breast cancer | |
SG10202011339RA (en) | Microrna biomarker for the diagnosis of gastric cancer | |
HK1246828A1 (en) | Biomarker panel for the detection of cancer | |
HK1247276A1 (en) | Biomarkers for pancreatic cancer | |
PL3474736T3 (en) | Olfactory detector for early diagnosis of ovarian cancer | |
IL251376A0 (en) | Methods for assessing risk of developing breast cancer | |
IL270717A (en) | Biomarkers for diagnosis of lung cancer | |
HK1248803A1 (en) | Specific biomarker set for non-invasive diagnosis of liver cancer | |
EP3606507A4 (en) | Serological biomarkers for early diagnosis of lung cancer | |
SG10202110526WA (en) | Biomarkers for cancer therapeutics | |
GB201719639D0 (en) | Setection of biomarkers | |
SG10201913528PA (en) | Methods of diagnosing cancer | |
GB201500584D0 (en) | Cancer biomarkers | |
IL266199A (en) | Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody | |
SG11201701875YA (en) | Methods for detecting ovarian cancer | |
SG11201701076TA (en) | Diagnosis of cancer | |
GB201619808D0 (en) | Biomarkers for the prognosis and diagnosis of cancer | |
GB201517028D0 (en) | Novel biomarkers for pancreatic cancer | |
HK1249134A1 (en) | Biomarkers for colorectal cancer related diseases | |
EP3189332A4 (en) | Biomarkers for detection of breast cancer | |
HK1250582A1 (en) | Pd-ecgf as biomarker of cancer | |
EP3278111A4 (en) | Biomarkers for detection of ovarian cancer | |
GB201617722D0 (en) | Method for determining prognosis of cancer | |
ITUA20162478A1 (en) | NEW DIAGNOSTIC AND PROGNOSTIC MARKERS FOR OVARIAN CANCER |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |